In with the new, out with the old… Byetta vs. Victoza… Sometimes changing up diabetes meds can kind of feel like dealing with temperamental pets.
Thanks to the talented Mike Durbin, who blogs at My Diabetic Heart and shared recently that he’s switched up his own diabetes meds. Hope the new med regime is going well and that your new dog Vic isn’t biting, Mike!
…
The biggest thing in diabetes headlines of late is Bydureon, the first and only once-a-week drug to help type 2 diabetics keep their sugars in check, which is newly approved by the FDA. Amylin’s stock price is up, and the pharma blogosphere is all abuzz. But if you’re like us, you may be wondering what the really big deal is. New type 2 drugs come out all the time, don’t they?
Well, for one thing,…
The world of type 2 diabetes drugs is wacky indeed. While Amylin’s long-acting version of Byetta — called Bydureon and predicted by many experts to become a blockbuster — is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred.
The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that…
Our controversial columnist Wil Dubois is back with another spicy edition of our new diabetes advice column, Ask D’Mine.
{Need help navigating life with diabetes? Email us at AskDMine@diabetesmine.com}
You know the answers you get here will be brutally honest and interesting, to say the least.
Robyn from Colorado, type 1, writes: I have traveled a lot over the years with my insulin in tow. Upon completion of each trip I always come to the…
Read more »